NYSEAMERICAN:OGEN Oragenics (OGEN) Stock Price, News & Analysis $0.21 +0.01 (+6.06%) Closing price 04:10 PM EasternExtended Trading$0.21 0.00 (-0.48%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsOwnershipSEC Filings About Oragenics Stock (NYSEAMERICAN:OGEN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oragenics alerts:Sign Up Key Stats Today's Range$0.18▼$0.2150-Day Range$0.20▼$0.5252-Week Range$0.17▼$1.11Volume671,660 shsAverage Volume2.57 million shsMarket Capitalization$947.10 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Oragenics is a biotechnology company developing intranasal drug candidates for neurological conditions. Its lead program, ONP-002, is an investigational treatment for concussion, also known as mild traumatic brain injury. The company is studying the candidate’s potential to reach the brain through nasal delivery; it is not an approved treatment. Oragenics previously focused on oral health and infectious-disease programs, including probiotics and lantibiotics, a class of antimicrobial compounds. The company later shifted its focus toward neurological disorders and obtained rights to develop ONP-002.AI Generated. May Contain Errors. Read More Oragenics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreOGEN MarketRank™: 0.365089940035 of 5 starsOragenics scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Oragenics. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioOragenics has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted22.08% of the float of Oragenics has been sold short.Short Interest Ratio / Days to CoverOragenics has a short interest ratio ("days to cover") of 40.07, which indicates bearish sentiment.Change versus previous monthShort interest in Oragenics has recently decreased by 0.15%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOragenics does not currently pay a dividend.Dividend GrowthOragenics does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.46 News SentimentOragenics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Oragenics this week, compared to 0 articles on an average week.Search Interest2 people have searched for OGEN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oragenics insiders have not sold or bought any company stock.Percentage Held by Insiders16.10% of the stock of Oragenics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions18.71% of the stock of Oragenics is held by institutions.Read more about Oragenics' insider trading history. Receive OGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oragenics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OGEN Stock News HeadlinesOragenics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 13, 2026 | marketscreener.comMOragenics Receives NYSE American Approval of Compliance Plan and Extension Through February 2028November 12, 2026 | globenewswire.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 17 at 1:00 AM | Weiss Ratings (Ad)Oragenics (NYSEAMERICAN:OGEN) Shares Climb 0.1% - Time to Buy?November 7, 2026 | americanbankingnews.comOragenics IncOctober 22, 2026 | money.usnews.comOragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation ForumSeptember 16, 2026 | globenewswire.comOragenics, Inc.: Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing UpdateAugust 30, 2026 | finanznachrichten.deOragenics Faces NYSE Compliance Challenges Amid Trial ProgressAugust 28, 2026 | tipranks.comSee More Headlines OGEN Stock Analysis - Frequently Asked Questions How have OGEN shares performed this year? Oragenics' stock was trading at $0.78 on January 1st, 2026. Since then, OGEN stock has decreased by 73.1% and is now trading at $0.21. How were Oragenics' earnings last quarter? Oragenics, Inc. (NYSEAMERICAN:OGEN) released its quarterly earnings results on Thursday, November, 12th. The company reported ($0.58) earnings per share (EPS) for the quarter. When did Oragenics' stock split? Oragenics's stock reverse split on Monday, January 23rd 2023.The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Oragenics? Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oragenics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oragenics investors own include Bionano Genomics (BNGO), Jaguar Animal Health (JAGX), Tonix Pharmaceuticals (TNXP), NIO (NIO), Tesla (TSLA), Ocugen (OCGN) and Plug Power (PLUG). Company Calendar Last Earnings11/12/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (34m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 OGEN's financial health is in the Red zone, according to TradeSmith. OGEN has been in this zone for over 34 months. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSEAMERICAN:OGEN Previous SymbolNYSE:OGEN CIK1174940 Webwww.oragenics.com Phone813-286-7900Fax813-286-7904Employees3Year FoundedN/AProfitability EPS (Trailing Twelve Months)($21.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.84 million Net MarginsN/A Pretax MarginN/A Return on Equity-200.12% Return on Assets-146.11% Debt Debt-to-Equity RatioN/A Current Ratio1.50 Quick Ratio1.50 Sales & Book Value Annual Sales$40 thousand Price / Sales23.68 Cash FlowN/A Price / Cash FlowN/A Book Value$0.24 per share Price / Book0.88Miscellaneous Outstanding Shares4,510,000Free Float3,786,000Market Cap$947.10 thousand OptionableN/A Beta1.28 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NYSEAMERICAN:OGEN) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oragenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oragenics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.